Stay updated on Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial
Sign up to get notified when there's something new on the Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial page.

Latest updates to the Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedRevision: v3.5.0 was added and Revision: v3.4.3 was removed.SummaryDifference0.1%

- Check18 days agoChange DetectedMetadata updates include adding the topic 'Type 2 diabetes' and the related topic 'MedlinePlus Genetics', and the site revision updated from v3.4.2 to v3.4.3.SummaryDifference0.2%

- Check25 days agoChange DetectedRemoved 'Type 2 diabetes' and 'MedlinePlus Genetics' from the Related Topics section.SummaryDifference0.2%

- Check33 days agoChange DetectedAdded related topics: Type 2 diabetes and MedlinePlus Genetics.SummaryDifference0.2%

- Check40 days agoChange DetectedThe page no longer lists 'Type 2 diabetes' as a condition and removes the related topic 'MedlinePlus Genetics'.SummaryDifference0.2%

- Check47 days agoChange DetectedRevision: v3.4.2 was added to the page, and the temporary government funding/operating status notice was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial page.